North America Transplant Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2022 –2029 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
USD 52.62 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
|
>Marché nord-américain du diagnostic de transplantation, par type de produit (instrument de diagnostic de transplantation, logiciel de diagnostic de transplantation, réactif de diagnostic de transplantation), technologie (dosages moléculaires basés sur la PCR, dosages moléculaires basés sur le séquençage), type de transplantation (transplantation d'organe solide, transplantation de cellules souches, transplantation de tissus mous, transplantation de moelle osseuse, autres transplantations), application (applications de diagnostic, applications de recherche), utilisateur final (laboratoires de recherche et instituts universitaires, centres hospitaliers et de transplantation, prestataires de services commerciaux, autres), canal de distribution (appel d'offres direct, ventes au détail, autres) Tendances de l'industrie et prévisions jusqu'en 2029.
Analyse et perspectives du marché du diagnostic de transplantation en Amérique du Nord
Le diagnostic de transplantation est une procédure de diagnostic généralement divisée en procédures pré-transplantation et post-transplantation. Elle permet d'analyser l'état de santé du patient. Si cela est évité, la personne immunodéprimée risque de développer une infection nosocomiale ou pire, ce qui peut entraîner la mort. La procédure est une collaboration harmonieuse entre les professionnels de la santé et les experts de laboratoire, garantissant de meilleurs résultats pour les patients. En outre, une correspondance étroite des marqueurs HLA du donneur et du receveur est importante. Cela augmente la probabilité de survie du greffon et minimise les complications graves de la transplantation immunologique. La prévalence accrue des maladies chroniques au sein de la population mondiale est susceptible de stimuler l'expansion du marché au cours des années de prévision. En outre, l'utilisation croissante de la thérapie par cellules souches et des médicaments personnalisés gagne en popularité. L'utilisation de nouvelles techniques de diagnostic a amélioré les résultats médicaux des transplantations d'organes. Le taux de rejet d'organes peut être réduit en faisant correspondre la compatibilité du donneur et du receveur avant la transplantation.
Cependant, le coût élevé des procédures associées aux instruments de diagnostic PCR et NGS est l'un des plus importants. Par conséquent, la croissance du marché pourrait être entravée à long terme. Le coût des équipements médicaux est l'un des éléments qui peuvent poser problème aux fournisseurs d'appareils de diagnostic de transplantation essentiels.
Data Bridge Market Research estime que le marché nord-américain du diagnostic de transplantation devrait atteindre une valeur de 4 194,68 millions USD d'ici 2029, à un TCAC de 6,9 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable pour 2019-2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales and Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
Hologic, Inc., Biofortuna Limited, Takara Bio Inc., Abbott, Diagnóstica Longwood SL, Adaptive Biotechnologies, NanoString, Arquer Diagnostics Ltd, altona Diagnostics GmbH, ELITechGroup, DiaSorin S.p.A., Horiba Ltd, EUROFINS VIRACOR, CareDx Inc., Laboratory Corporation of America Holdings., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., Preservation Solutions, Inc., TransMedics, Transonic, Stryker, Bio-Rad Laboratories, Inc., Zimmer Biomet, QIAGEN, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX, Illumina, Inc., Luminex Corporation (A subsidiary of DiaSorin Company), IMMUCOR, among others |
Market Definition
Transplant diagnostics are the immunogenetics and histocompatibility of organ and hematopoietic stem cell transplantations. These diagnostics help healthcare professionals determine compatibility between potential recipients and organ donors. These are used in various disciplines, such as immunogenetics, pathology, and infectious diseases, among others. Transplant diagnostics are used to determine whether the donor and the recipient of the organ are compatible before or after the transplant. With the introduction of transplant diagnostics, the prevalence of diseases that can cause organ failure, including both pre-and post-transplant screening, is expected to explode. The market has attracted the interest of healthcare professionals due to the many advantages these tests offer to verify suitability for a transplant procedure. Organ transplantation is one of the most popular treatment options for many end-stage renal disease patients on continuous dialysis.
In addition, it is possible to investigate organ transplantation for cases involving the heart, liver, or bone marrow. Although in many cases, there is a strong association between renal failure and liver transplantation, including end-stage renal disease. New transcriptomic, proteomic, and genomic indicators in molecular diagnostics can help to better tailor transplant therapy and early detection of rejection events. Also, strategic initiatives by market players, technological progressions in transplant diagnostics, high sterility assurance, and increasing investment in healthcare infrastructure increase the demand for transplant diagnostics.
North America Transplant Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising number of transplant procedures
The demand for organ transplantation has rapidly increased worldwide during the past decade due to the increased incidence of vital organ failure and improved post-transplant outcomes. Demand for kidney, heart, liver and lungs transplant is very high. Alcohol consumption, lack of exercise and drug abuse are leading causes of organ failure. The number of living donor transplants has been affected by the COVID-19 pandemic. But living donor transplants have increased by 14.2 percent over 2020.
- In addition, organ transplantation improves patient survival and quality of life and has a major positive impact on public health and the socioeconomic burden of organ failure. The European Union (EU) has a relatively uniform and structured approach to organ transplantation, well-developed national programs, international systems to facilitate organ sharing and well-defined exchange policies, making Europe a leader in this field.
Thus, the increasing number of transplant procedures across the globe and the increase in successful transplantations is expected to boost the North America transplant diagnostics market.
- Increase in the technological advancements in the field of transplants
New technologies are rapidly changing traditional approaches to organ transplantation. The main challenges in organ transplantation are how best to identify and, if possible, eliminate the need for lifelong immunosuppression and how to expand the pool of donors suitable for human transplantation. Researchers have developed an advanced system where transport time can be extended by tricking donor organs into thinking they are still inside the body. This system keeps oxygenated blood flowing through the organs to delay tissue death. A normothermic perfusion machine mimics the human body, ensuring constant blood flow to the organ. The machine can also deliver drugs or other nutrients to keep the liver in optimal condition before the transplant.
In addition, bio-artificial organ production techniques are a range of enabling techniques that can be used to produce human organs based on bionic principles. Over the past ten years, significant progress has been made in developing various organ manufacturing technologies. The past decade has seen tremendous advances in new technologies such as single-cell RNA sequencing, Nano biotechnology and CRISPR-Cas9 gene editing. However, creative applications of such new and powerful technologies to improve clinical transplantation have only begun. With such tools, there are now good opportunities to make major breakthroughs in defining and providing optimized and individualized care for all organ transplants.
Restraint
- High cost of organ transplantation
Organ transplantation therapy employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing players. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Also, organ transplants are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation and expensive medications.
- In addition, desensitizing therapies have also been used to achieve transplantation from an incompatible donor. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.
Thus, the high cost of transplantation and treatment using advanced modalities and technology products will act as a major restraining factor for the growth of the North America transplant diagnostics market.
Opportunity
-
Strategic initiatives by market players
The rise in the North America transplant diagnostics market increases the need for strategic business ideas. It includes a partnership, business expansion and other development. The surge in demand for a donor organs is significantly increasing the demand for transplant diagnostic kits. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.
These strategic initiatives, such as product launches, agreements and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the North America transplant diagnostics market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may be expected to as an opportunity that helps them to drive the North America transplant diagnostics market.
Challenge
- Ethical challenges faced during organ transplantation
The surge in the incidence of failure of vital organs and inadequate supply of organs has created a wide gap between organ supply and organ demand. The issue has resulted in long approval times to receive an organ and a rise in deaths. The events, which occurred in the previous years and continue in the present, have raised many ethical, moral and societal issues regarding supply, the methods of organ allocation and the use of living donors as volunteers, including minors.
Lack of accuracy in reporting, the donated organs can't be supplied and procedures that neither relieve suffering nor prolong life are rapidly identified.
Issues such as lack of organ procurement, religious acceptance, brain death and misconceptions related to organ donation and transplantation are still present on many ethical personal and community levels, even within the medical community. The various aspects of ethical, cultural and religious nature should not be a barrier to the act of organ donation and transplantation all of these are issues to be solved. Therefore, ethical challenges faced during organ transplantation are expected to challenge market growth.
Post-COVID-19 Impact on North America Transplant Diagnostics Market
North America transplant diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics has greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the North America transplant diagnostics market.
Recent Developments
- In July 2022, Horiba Medical launched a brand new product in its Yumizen Hematology Category. The product has new and advanced characteristics to satisfy the needs of various clinical as well as laboratory requirements. This has helped the company to diversify its product offerings
- In January 2022, Hoffmann-La Roche Ltd introduced Cobas Infinity edge, a cloud-based point-of-care platform accessible. With its advanced technology, healthcare practitioners can handle patient data. This has helped the company to diversify their product line
North America Transplant Diagnostics Market Scope
North America transplant diagnostics market is segmented into product type, technology, transplant type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product Type
- Transplant Diagnostic Instrument
- Transplant Diagnostic Software
- Transplant Diagnostic Reagent
On the basis of product type, the North America transplant diagnostics market is segmented into transplant diagnostic instrument, transplant diagnostic software, transplant diagnostic reagent.
Technology
- PCR-Based Molecular Assays
- Sequencing-Based Molecular Assays
On the basis of technology, the North America transplant diagnostics market is segmented into PCR-based molecular assays, and sequencing-based molecular assays.
Transplant Type
- Solid Organ Transplantation
- Stem Cell Transplantation
- Soft Tissue Transplantation
- Bone Marrow Transplantation
- Other Transplants
On the basis of transplant type, the North America transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, bone marrow transplantation, and other transplants.
Application
- Diagnostic Applications
- Research Applications
On the basis of application, the North America transplant diagnostics market is segmented into diagnostic applications and research applications.
End User
- Research Laboratories and Academic Institutes
- Hospitals and Transplant Centers
- Commercial Service Providers
- Others
On the basis of end user, the North America transplant diagnostics market is segmented into research laboratories and academic institutes, hospitals and transplant centers, commercial service providers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the North America transplant diagnostics market is segmented into direct tender, retail sales, and others.
North America Transplant Diagnostics Market Regional Analysis/Insights
North America transplant diagnostics market is analyzed, and market size information is provided by country, product type, technology, transplant type, application, end user, and distribution channel.
Some countries covered in the North America transplant diagnostics market are the U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America transplant diagnostics market due to the presence of key market players in the largest consumer market with high GDP.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the market's current and future trends. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Transplant Diagnostics Market Share Analysis
Le paysage concurrentiel du marché nord-américain du diagnostic de transplantation fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la portée du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché nord-américain du diagnostic de transplantation.
Français Certains des principaux acteurs opérant sur le marché du diagnostic de transplantation en Amérique du Nord sont Hologic, Inc., Biofortuna Limited, Takara Bio Inc., Abbott, Diagnóstica Longwood SL, Adaptive Biotechnologies, NanoString, Arquer Diagnostics Ltd, altona Diagnostics GmbH, ELITechGroup, DiaSorin SpA, Horiba Ltd, EUROFINS VIRACOR, CareDx Inc., Laboratory Corporation of America Holdings., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., Preservation Solutions, Inc., TransMedics, Transonic, Stryker, Bio-Rad Laboratories, Inc., Zimmer Biomet, QIAGEN, F. Hoffmann-La Roche Ltd, BIOMÉRIEUX, Illumina, Inc., Luminex Corporation (Une filiale de DiaSorin Company), IMMUCOR, entre autres.
Méthodologie de recherche : Marché nord-américain des diagnostics de transplantation
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent une grille de positionnement des fournisseurs, une analyse de la chronologie du marché, un aperçu et un guide du marché, une grille de positionnement des entreprises, une analyse des parts de marché des entreprises, des normes de mesure, l'Amérique du Nord par rapport aux régions et une analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 EPIDEMOLOGY
3.2 PESTEL_ANALYSIS
3.3 PORTER'S FIVE FORCE
3.4 TECHNOLOGICAL INNOVATIONS
4 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS
5 KEY STRATEGIC INITIATIVES
6 INDUSTRIAL INSIGHTS:
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES
7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS
7.1.3 RISING HEALTHCARE SPENDING
7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF ORGAN TRANSPLANTATION
7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION
7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION
7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY
8 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS
8.2.1 AUTOMATED PIPETTORS & DISPENSERS
8.2.2 AUTOMATED SYSTEMS
8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM
8.2.2.2 PCR SETUP
8.2.2.3 OTHERS
8.2.3 NGS INSTRUMENTS
8.2.4 READERS & ANALYZERS
8.2.5 TRANSPLANT DIAGNOSTIC KITS
8.2.5.1 ASPERGILLUS SPP KITS
8.2.5.2 P. JIROVECII KITS
8.2.5.3 CMV KITS
8.2.5.4 EBV KITS
8.2.5.5 BKV KITS
8.2.5.6 VZV KITS
8.2.5.7 HSV1 KITS
8.2.5.8 HSV2 KITS
8.2.5.9 PARVOVIRUS B19 KITS
8.2.5.10 ADENOVIRUS KITS
8.2.5.11 ENTEROVIRUS KITS
8.2.5.12 JCV KITS
8.2.5.13 HHV6 KITS
8.2.5.14 HHV7 KITS
8.2.5.15 HHV8 KITS
8.2.5.16 TOXOPLASMA GONDII KITS
8.2.5.17 HEPATITIS E KITS
8.2.5.18 OTHER KITS
8.2.6 OTHER KITS
8.3 TRANSPLANT DIAGNOSTIC SOFTWARE’S
8.3.1 DNA SOFTWARE
8.3.2 NGS SOFTWARE
8.3.3 DATA MANAGEMENT SOFTWARE
8.3.4 OTHER SOFTWARE’S
8.4 TRANSPLANT DIAGNOSTIC REAGENTS
8.4.1 MONOCLONAL ANTIBODIES
8.4.2 CYTOTOXIC CONTROLS
8.4.3 HUMAN SERUM
8.4.4 OTHER REAGENTS
9 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 PCR-BASED MOLECULAR ASSAYS
9.2.1 REAL TIME PCR
9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR
9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP)
9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS
9.3 SEQUENCING-BASED MOLECULAR ASSAYS
9.3.1 SANGER SEQUENCING
9.3.2 NEXT GENERATION SEQUENCING
9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS.
10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE
10.1 OVERVIEW
10.2 SOLID ORGAN TRANSPLANTATION
10.2.1 KIDNEY TRANSPLANTATION
10.2.2 LIVER TRANSPLANTATION
10.2.3 HEART TRANSPLANTATION
10.2.4 LUNG TRANSPLANTATION
10.2.5 PANCREAS TRANSPLANTATION
10.2.6 OTHER ORGAN TRANSPLANTATIONS
10.3 STEM CELL TRANSPLANTATION
10.3.1 BONE MARROW TRANSPLANT (BMT)
10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT
10.3.3 CORD BLOOD TRANSPLANT
10.3.4 OTHER STEM CELL TRANSPLANTS
10.4 SOFT TISSUE TRANSPLANTATION
10.4.1 SKIN GRAFT
10.4.2 CARTILAGE TRANSPLANTATION
10.4.3 ADRENAL AUTOGRAFTING
10.4.4 OTHER SOFT TISSUE TRANSPLANTATION.
10.5 BONE MARROW TRANSPLANTATION
10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT
10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT
10.5.3 UMBILICAL CORD BLOOD TRANSPLANT.
10.6 OTHERS
11 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DIAGNOSTIC APPLICATIONS
11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT
11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS
11.2.1.2 AUTOMATED SYSTEMS
11.2.1.3 NGS INSTRUMENTS
11.2.1.4 READERS & ANALYZERS
11.2.1.5 TRANSPLANT DIAGNOSTIC KITS
11.2.1.6 OTHERS
11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE
11.2.2.1 DNA SOFTWARE
11.2.2.2 NGS SOFTWARE
11.2.2.3 DATA MANAGEMENT SOFTWARE
11.2.2.4 OTHER SOFTWARES
11.2.3 TRANSPLANT DIAGNOSTIC REAGENT
11.2.3.1 MONOCLONAL ANTIBODIES
11.2.3.2 CYTOTOXIC CONTROLS
11.2.3.3 HUMAN SERUM
11.2.3.4 OTHER REAGENTS
11.3 RESEARCH APPLICATIONS
11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT
11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS
11.3.1.2 AUTOMATED SYSTEMS
11.3.1.3 NGS INSTRUMENTS
11.3.1.4 READERS & ANALYZERS
11.3.1.5 TRANSPLANT DIAGNOSTIC KITS
11.3.1.6 OTHERS
11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE
11.3.2.1 DNA SOFTWARE
11.3.2.2 NGS SOFTWARE
11.3.2.3 DATA MANAGEMENT SOFTWARE
11.3.2.4 OTHER SOFTWARES
11.3.3 TRANSPLANT DIAGNOSTIC REAGENT
11.3.3.1 MONOCLONAL ANTIBODIES
11.3.3.2 CYTOTOXIC CONTROLS
11.3.3.3 HUMAN SERUM
11.3.3.4 OTHER REAGENTS
12 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS AND TRANSPLANT CENTERS
12.3 COMMERCIAL SERVICE PROVIDERS
12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
12.5 OTHERS
13 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 F. HOFFMANN LA ROCHE LTD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 TAKARA BIO INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 HOLOGIC, INC
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ADAPTIVE BIOTECHNOLOGIES
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ALTONA DIAGNOSTICS
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ARQUER DIAGNOSTICS LTD
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BAG DIAGNOSTICS GMBH
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BIOFORTUNA LIMITED
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BIOMÉRIEUX
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BIO-RAD LABORATORIES, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOTYPE GMBH
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 CAREDX INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 CLONIT SRL
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 DIAGNOSTICA LONGWOOD SL
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 DIASORIN S.P.A.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 ELITECHGROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 EUROFINS VIRACOR
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 HORIBA LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 ILLUMINA, INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 IMMUCOR
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENTS
17.23 LABORATORY CORPORATION OF AMERICA HOLDINGS.
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 LUMINEX CORPORATION. (A SUBSIDIARY OF DIASORIN)
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 NANOSTRING
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 PATHONOSTICS
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENTS
17.27 PRESERVATION SOLUTIONS, INC.
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 QIAGEN
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 RANDOX LABORATORIES LTD.
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
17.3 STRYKER
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENT
17.31 TRANSMEDICS
17.31.1 COMPANY SNAPSHOT
17.31.2 REVENUE ANALYSIS
17.31.3 PRODUCT PORTFOLIO
17.31.4 RECENT DEVELOPMENTS
17.32 TRANSONIC.
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENT
17.33 ZIMMER BIOMET
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE’S IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE’S IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA BONE MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA BONE MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH APPLICATIONS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA RESEARCH APPLICATIONS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS AND TRANSPLANT CENTERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA COMMERCIAL SERVICE PROVIDERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA RESEARCH LABORATORIES AND ACADEMIC INSTITUTES IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA DIRECT TENDER IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA RETAIL SALES IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 62 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 65 NORTH AMERICA RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 66 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 68 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 69 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.S. AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 74 U.S. AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 75 U.S. AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.S. TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 77 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 78 U.S. TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 79 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 80 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 82 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 83 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 84 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 86 U.S. TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 87 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 U.S. PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 U.S. SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 90 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 91 U.S. SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.S. STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.S. SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 94 U.S. BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 95 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 U.S. DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.S. RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 101 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 104 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 105 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 106 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 108 CANADA AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 109 CANADA AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 110 CANADA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 CANADA TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 112 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 113 CANADA TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 114 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 115 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 116 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 117 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 118 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 119 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 120 CANADA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 121 CANADA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 122 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 123 CANADA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 124 CANADA SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 125 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 126 CANADA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 127 CANADA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 128 CANADA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 129 CANADA BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 130 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 CANADA DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 132 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 133 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 134 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 135 CANADA RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 136 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 137 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 138 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 139 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 142 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 143 MEXICO AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 144 MEXICO AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 145 MEXICO AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 146 MEXICO TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 147 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 148 MEXICO TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 149 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 150 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 151 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 152 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 153 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 154 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 155 MEXICO TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 156 MEXICO TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 157 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 158 MEXICO PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 159 MEXICO SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 160 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 161 MEXICO SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 162 MEXICO STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 163 MEXICO SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 164 MEXICO BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 165 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 166 MEXICO DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 167 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 168 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 169 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 170 MEXICO RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 171 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 172 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 173 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 175 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASING USE OF TRANSPLANT DIAGNOSTICS IS EXPECTED TO DRIVE THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 TRANSPLANT DIAGNOSTIC INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2021
FIGURE 15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2021
FIGURE 19 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2021
FIGURE 23 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2021
FIGURE 27 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2021
FIGURE 31 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 43 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
